Ariose Capital Management Limited

Ariose Capital Management Limited is a private investment firm specializing in healthcare and biotechnology investments across various stages and geographies. The firm focuses on private equity and venture capital investments, targeting early-stage, growth, and late-stage opportunities. Their geographical focus includes the United States, China, Hong Kong, the United Kingdom, Germany, France, Japan, South Korea, India, Australia, Brazil, Canada, Mexico, South Africa, Russia, Saudi Arabia, the United Arab Emirates, Singapore, Malaysia, and Indonesia. The firm invests in a wide range of industries, including healthcare, biotechnology, technology, consumer goods, energy, financial services, real estate, telecommunications, media, retail, transportation, industrial goods, materials, utilities, and agriculture. Investment sizes range from $5 million to $50 million. Ariose Capital Management Limited has a history of active participation in investor relations activities, including specific object research, analyst meetings, media interviews, performance briefings, press conferences, roadshows, site visits, one-on-one communications, and other activities such as conference calls. Their portfolio includes investments in companies like 百济神州有限公司 (BeiGene, Ltd.), a biotechnology company listed on the Shanghai Stock Exchange (A-share code: 688235), Hong Kong Stock Exchange (H-share code: 06160), and NASDAQ (BGNE).

Focus on healthcare and biotechnology sectors, Investments in early-stage, growth, and late-stage companies, Geographical focus on United States, China, Hong Kong, and other specified countries, Investment sizes between $5 million and $50 million